Martin Mackay to head research at AstraZeneca

Will have accountability for delivering new products

Scotsman Martin Mackay is to leave Pfizer to take up the newly created position of president of r&d at AstraZeneca. He will have overall accountability for delivering new products – small molecules and biologics – from the Anglo-Swedish pharmaceutical company’s pipeline. He will start his new role on 1 July and will be based at the company’s headquarters in London, UK.

Mackay currently heads up Pfizer’s PharmaTherapeutics Research & Development division and is a member of the Pfizer Executive Leadership Team.

Prior to joining Pfizer in 1995, Mackay held several discovery and development roles culminating with his appointment as head of Molecular and Cell Biology, CNS Research at Ciba-Geigy.

Mackay has a first class honours degree in Microbiology from Heriot-Watt University and a PhD in Molecular Genetics from the University of Edinburgh.

‘Martin has impeccable scientific and leadership credentials combined with extensive experience of the pharmaceutical industry. I am delighted he is joining us,’ said David Brennan, chief executive of AstraZeneca. ‘We have a clear and unambiguous commitment to creating value through innovative biopharmaceuticals with research and development at the heart of our strategy.’

Mackay will report to Brennan and will be a member of AstraZeneca’s Senior Executive Team.

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Drug Delivery

Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle

AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Research & Development

BenevolentAI and AstraZeneca collaboration leads to novel lupus target discovery

The novel target will be added to AstraZeneca's drug development pipeline for lupus, an autoimmune disease with significant unmet needs in the patient population
Research & Development

AstraZeneca presents data at ATS 2024 highlighting tezepelumab’s potential in treating COPD

Late-breaking results from the Phase IIa COURSE trial provide insight into tezepelumab's impact on COPD exacerbations in patients with a broad range of eosinophil levels
Research & Development

BenevolentAI and AstraZeneca collaboration finds novel heart failure target

The heart failure target was discovered through an AI platform, with AstraZeneca then experimentally validating its clinical potential
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Subscribe now